In this international non-interventional post-marketing surveillance study we want to
evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib
(Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the
tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the
duration of Sorafenib treatment.